West Announces Second-Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
West Pharma (WST) Tops Q2 EPS by 34c, Revenues Beat; Raises FY20 EPS/Revenue Guidance Above Consensus
July 23, 2020 6:15 AM EDTWest Pharma (NYSE: WST) reported Q2 EPS of $1.25, $0.34 better than the analyst estimate of $0.91. Revenue for the quarter came in at $527.2 million versus the consensus estimate of $496.09 million.
Second-Quarter 2020 Summary (comparisons to prior-year period)
Net sales of $527.2 million grew 12.2%; organic sales growth was 14.3%.Reported-diluted EPS of $1.21 increased 38%.Adjusted-diluted EPS of $1.25 increased 40%.Company is raising full-year 2020 net sales guidance to a new range of between $2.035 billion and $2.055 billion.Company is raising full-year 2020 adjusted-diluted EPS guidance to a new range of between $4.15 and $4.25."Adjusted-diluted EPS"... More
